X-Chem, a leading provider of early-stage drug discovery solutions, has recently appointed Dr. Erin Davis as their new chief technology officer. Dr. Davis brings a wealth of experience in data strategy, informatics, computational chemistry, and software solutions to the realm of drug discovery. Her addition to X-Chem’s executive team signifies the company’s focus on utilizing data generation platforms and digital solutions to enhance their service offerings to clients.
With expertise in DNA-encoded library technology, discovery and synthetic chemistry, and machine learning powered by their proprietary ArtemisAI platform, X-Chem is well positioned to revolutionize drug discovery through the integration of real-world data generation and advanced machine learning strategies. CEO Karen Lackey expressed excitement about Dr. Davis joining the team, emphasizing her creativity and track record of innovation. Together, the team at X-Chem aims to redefine the landscape of small molecule drug discovery.
X-Chem specializes in small molecule discovery, offering pharmaceutical and biotech companies a comprehensive solution for screening, hit validation, and lead optimization. By leveraging DNA-encoded chemical library (DEL) technology and their proprietary artificial intelligence platform, ArtemisAI, the company is able to identify novel small molecule leads for challenging therapeutic targets. With expertise in medicinal chemistry, custom synthesis, and scale-up process chemistry, X-Chem supports all stages of small-molecule drug discovery from initial screening to candidate identification.
